Join CBMTG | Print Page | Contact Us | Sign In
Upcoming Webinars

 

The University of British Columbia Division of Continuing Professional Development (UBC CPD) is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME) to provide study credits for continuing medical education for physicians.  This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and has been approved by UBC CPD for up to 10.0 MOC Section 1 Group Learning credits. Each physician should claim only those credits he/she actually spent in the activity.


Wednesday, February 13, 2019
9:00am PT/12:00pm ET
CME CREDIT HOURS: 1.0


CAR-T Cells: A Pediatric Perspective

Joerg Krueger, MD (Hospital for Sick Children, Toronto, Ontario)

Learning Objectives:
TBA

 


Wednesday, March 6, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0

Current Management of Waldenstrom Macroglobulinemia

Jorge J. Castillo, MD (Dana-Farber Cancer Institute, Boston, Massachusetts)

Speaker Biography:
Dr. Castillo was born in Peru, received his medical degree in Mexico City, and completed his Internal Medicine and Hematology & Oncology training at the University of Massachusetts and Brown University, respectively. In 2013, Dr. Castillo was appointed Assistant Professor at Harvard Medical School. Dr. Castillo is the Clinical Director of the Bing Center for Waldenström Macroglobulinemia at the Dana-Farber Cancer Institute, and he sees approximately 1,000 patients with Waldenström Macroglobulinemia per year in his Clinic. Dr. Castillo is also the principal investigator in a series of innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Dr. Castillo is a member of the NCCN Committee for Myeloma, Amyloidosis and Waldenström Macroglobulinemia. He has authored more than 200 peer-reviewed articles, and has published his research in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Blood.

Learning Objectives:
1. Discuss the biology and pathogenesis of Waldenstrom macroglobulinemia
2. Review clinicopathological features of Waldenstrom macroglobulinemia
3. Provide an update treatment options in Waldenstrom macroglobulinemia, including the role of transplantation



Wednesday, April 10, 2019
9:00am PT/12:00pm ET
CME CREDIT HOURS: 1.0

Hematopoietic Stem Cell Donation and the Canadian Registry

David Allan, MD, FRCPC (Ottawa Hospital Research Institute, Ottawa, Ontario)
 
Learning Objectives:
TBA


Wednesday, May 22, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0


Drug Related Issues in BMT

Lee Dupuis, RPh, ACPR, FCSHP, PhD (Hospital for Sick Children, Toronto, Ontario)

Learning Objectives:
TBA


Wednesday, June 2019
TIME TBD
CME CREDIT HOURS: 1.0


Gynecological Issues Post-Transplant

Michelle Jacobson, MD (Women’s College Hospital, Mount Sinai, Toronto, Ontario)

Learning Objectives:
TBA



Wednesday, September 11, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0

Counting CD34+ Cells in the Clinical Transplantation Setting: Interesting Cases and Implications for Assessment of Graft Adequacy

D. Robert Sutherland, PhD, BSc, MSc (University of Toronto, Toronto, Ontario)

Learning Objectives:
1. Review why we count CD34+ cells
2. Determine how we count CD34+ cells
3. Discuss how we develop International Guidelines
4. Review interesting cases with implications for assessment of graft adequacy



Wednesday, October 16, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0

Controversies in Use of High Dose Chemotherapy in Patients with Progressive Germ Cell Tumor Following Cisplatin-Based Combination Chemotherapy

Lawrence H. Einhorn, MD (Indiana University, Indianapolis, Indiana)

Learning Objectives:
1. Understand the rationale behind high dose chemotherapy with peripheral blood stem cell transplant
2. Appreciate the controversy of high dose versus standard dose salvage chemotherapy
3. Learn about managements of complications from high dose chemotherapy with peripheral blood stem cell rescue



Wednesday, November 6, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0

Integrating Chronic GvHD Biomarkers into the Clinical Evaluation of Chronic GvHD According to the National Institutes of Health Consensus Criteria

Geoff Cuvelier, MD, FRCPC (CancerCare Manitoba, Winnipeg, Manitoba)
 
Speaker Biography:
Dr. Geoff Cuvelier is the Director of Pediatric BMT within the Manitoba Blood and Marrow Transplant program at CancerCare Manitoba and Associate Professor of Pediatrics in the Max Rady Faculty of Health Sciences, Department of Pediatrics and Child and Health at the University of Manitoba.  Dr. Cuvelier has been the lead Co-PI for the multi-institutional Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) / Pediatric Blood and Marrow Transplant Consortium 1202 study that evaluated both the clinical evaluation of chronic GvHD in children, as well as prognostic cGvHD biomarkers used to predict which children are at higher risk for developing cGvHD.  
 
Synopsis:
In this talk, Dr. Cuvelier will discuss the evaluation of cGvHD according to the National Institutes of Health consensus criteria (applicable to both adults and children), the benefits and challenges with doing so in clinical practice, and how prognostic biomarkers present before the onset of cGvHD may be useful in the future in predicting which patients are at higher or lower risk for developing cGvHD.

 

Learning Objectives:
1. Have an appreciation for the National Institutes of Health Consensus Criteria (NIH-CC) for Chronic GvHD evaluation, including the difference between diagnostic, distinctive, common, and other manifestations of GVHD, and how these can be applied to the classification and evaluation of GvHD in clinical practice
2. Appreciate the benefits and challenges with the NIH-CC in evaluating cGvHD
3. Discuss how prognostic biomarkers may in the future be integrated into the risk assessment and evaluation of cGvHD

 

 


Wednesday, December 11, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0

Cellular Therapy Manufacturing – Clinical Trials and Hopes for the Future

David Courtman, MD (Ottawa Hospital Research Institute, Ottawa, Ontario)

Learning Objectives:
1. To gain an understanding of the regulatory requirements for clinical cell processing for products involving more than minimal manipulation or intended for non-homologous use.
2. Describe the infrastructure commonly used in cGMP manufacturing of experimental cell products.
3. Provide examples of clinical trial designs and outcome measures in advanced cell therapy trials.

 

This website is sponsored by an unrestricted educational grant from:

Follow CBMTG